Conference Coverage

Low-Volume Bowel Prep Easier, as Effective as Standard Prep in Hospitalized Patients


 

FROM ACG 2024

Ease of Use Is a Plus

On the basis of the Mayo Clinic Bowel Preparation survey, there wasn’t a difference between the groups in how much bowel prep solution was left in the bottle. However, more than twice as many patients who took MoviPrep said the prep was “easy,” and more MoviPrep patients called it “acceptable,” whereas more GoLYTELY patients said prep was “somewhat difficult” or “very difficult.”

In addition, significantly more MoviPrep patients (49.7% vs 33.7%) said they were “mostly willing” to drink the same prep again if they needed another colonoscopy in the future, while more GoLYTELY patients said they were “somewhat willing” (44.7% vs 34.6%) or “not willing at all” (21.6% vs 15.7%).

“Bowel prep, particularly in hospitals, is important because we do it so often. When you think about what our patients in the hospital are going through, they’re very sick and often have multiple comorbidities, so how can we give them a bowel prep that is safe for them, easiest for them, easy for our nursing staff who are experiencing shortages, and as good as the traditional bowel prep,” said the session’s moderator, Amy Oxentenko, MD, AGAF, professor of medicine and gastroenterologist at Mayo Clinic, Rochester, Minnesota.

professor of medicine and gastroenterologist at Mayo Clinic, Rochester, Minnesota Mayo Clinic

Dr. Amy Oxentenko

“Here we’ve seen great data that we can provide half the volume of the prep, still get amazing results in terms of adequacy of preparation, and the patients had a better experience,” said Oxentenko, the incoming ACG president. “That’s important because they likely may need another colonoscopy in the future, and we would hate for the bowel prep in the hospital to potentially dissuade them from a future colonoscopy.”

Future studies could stratify patients on the basis of colonoscopy indication or patient history, including conditions such as chronic constipation or neurogenic bowel, where some patients may still need a high-volume prep, Oxentenko said.

“Also, in the hospital setting, we don’t always know when a patient is going to the endoscopy suite due to other patient cases that may get prolonged or pushed in,” she said. “So how do you time the second dose of the split dose in anticipation of when that patient will go to the endoscopy suite to maintain that great preparation with a smaller volume prep?”

The study was awarded the ACG Governors Award for Excellence in Clinical Research (Trainee). Xiao and Oxentenko reported no relevant disclosures.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

Fecal Immunochemical Test Performance for CRC Screening Varies Widely
MDedge Hematology and Oncology
A CRC Blood Test Is Here. What Does it Mean for Screening?
MDedge Hematology and Oncology
FDA OKs Next-Gen Cologuard Test for CRC Screening
MDedge Hematology and Oncology
Molecular Stool Testing Could Cut Post-Polypectomy Colonoscopies by 15%-41%
MDedge Hematology and Oncology
Mortality Rates From Early-Onset CRC Have Risen Considerably Over Last 2 Decades
MDedge Hematology and Oncology
When It Comes to Polyp Diagnosis With CADx, Location Matters
MDedge Hematology and Oncology
Value of AI-Aided Colonoscopy on Advanced Neoplasia Detection Unclear
MDedge Hematology and Oncology
FIT Completion and Yield Similar in Younger and Older Adults
MDedge Hematology and Oncology
AI Tool Helps Detect, Differentiate Pancreatic Lesions During Endoscopic Ultrasound
MDedge Hematology and Oncology
GLP-1 RAs Reduce Early-Onset CRC Risk in Patients With Type 2 Diabetes
MDedge Hematology and Oncology